Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer

American Journal of Pathology

Volumn 148, Issue 6, 1996, Pages 2073-2082

  Järvinen, Tero A H ^a   Kononen, Juha ^a   Pelto Huikko, Markku ^b   Isola, Jorma ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ESTROGEN RECEPTOR; MESSENGER RNA; ONCOPROTEIN; PROGESTERONE RECEPTOR;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INDUCTION; BIOSYNTHESIS; BREAST TUMOR; CANCER INVASION; CANCER STAGING; CELL DIVISION; ENZYMOLOGY; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; PROTO ONCOGENE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; DNA TOPOISOMERASES, TYPE II; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RNA, MESSENGER;

EID: 0029665095     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Elledge RM, McGuire WL, Osborne CK: Prognostic factors in breast cancer. Semin Oncol 1992, 19:244-253
2. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994, 330:1260-1266
3. Chen AY, Liu LF: DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994, 34:191-218
4. Watt PM, Hickson ID: Structure and function of type II DNA topoisomerases. Biochem J 1994, 303:681-695
5. Holm C: Coming undone: how to untangle a chromosome. Cell 1994, 77:955-957
6. Roca J: The mechanism of DNA topoisomerases. Trends Biochem Sci 1994, 20:156-160
7. Roca J, Wang JC: DNA transport by a type II DNA topoisomerases: evidence in favor of a two-gate mechanism. Cell 1994, 77:609-616
8. Froelich-Ammon SJ, Osheroff N: Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J Biol Chem 1995, 270:21429-21432
9. Taagepera S, Rao PN, Drake FH, Gorbsky GL: DNA topoisomerase IIα is the major chromosome protein recognized by the mitotic phosphorprotein antibody MPM-2 recognized by the mitotic phosphoprotein antibody MPM-2. Proc Natl Acad Sci USA 1993, 90:8407-8411
10. Danks MK, Qiu J, Catapano CV, Schmidt CA, Beck WT, Fernandes DJ: Subcellular distribution of the α and β topoisomerase II-DNA complexes stabilized by VM-26. Biochem Pharmacol 1994, 48:1785-1795
11. Brown GA, McPherson JP, Gu L, Hedley DW, Toso R, Deuchars KL, Freedman MH, Goldenberg GJ: Relationship of DNA topoisomerase IIα and -β expression of cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res 1995, 55:78-82
12. Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, Harris AL, Hickson ID: Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 1995, 72:1454-1461
13. Davies SM, Robson CN, Davies SL, Hickson ID: Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 1988, 263:17724-17729
14. Fry AM, Chersta CM, Davies SM, Walker MC, Harris AL, Hartly JA: Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991, 51:6592-6596
15. Sulkes A, Livingston RB, Murphy WK: Tritiated thymidine labeling index and response in human breast cancer. J Natl Cancer Inst 1979, 62:513-515
16. Remvikos Y, Beuzeboc P, Zajdela A, Violemot N, Magdalenat H, Pouillart P: Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 1989, 81: 1383-1387
17. O'Reilly SM, Camplejohn RS, Rubens RD, Richards MA: DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer. Eur J Cancer 1992, 28:681-683
18. Hietanen P, Blomqvist C, Wasenius V-M, Niskanen E, Franssila K, Nordling S: Do DNA ploidy and S-phase fraction in primary tumor predict the response to chemotherapy in metastatic breast cancer. Br J Cancer 1995, 71:1029-1032
19. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL: Topoisomerase IIα co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993, 8:933-938
20. Keith WN, Douglas F, Wishart GC, McCallum HM, George WD, Kaye SB, Brown R: Co-amplification of erbB2, topoisomerase IIα and retinoid acid receptor genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer 1993, 29A:1469-1475
21. Matsumura K, Isola J, Chew K, Henderson C, Smith HS, Harris AL, Hickson ID, Waldman F: Topoisomerase II deletion as well as amplification associated with erbB2 amplification in breast cancer. Proc Am Assoc Cancer Res 1994, 35:2708a
22. Holden JA, Rolfson DH, Wittwer CT: The distribution of immunoreactive topoisomerase II protein in human tissues and neoplasms. Oncol Res 1992, 4:157-166
23. Holden JA, Snow GW, Perkins SL, Jolles CJ, Kjeldsberg CR: Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues. Mod Pathol 1994, 8:829-834
24. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K, Burke PJ: Topoisomerase II levels and drug sensitivity in adult myelogenous leukemia. Blood 1994, 83:517-530
25. Tuccari G, Rizzo A, Giuffre G, Barresi G: Immunocytochemical detection of DNA topoisomerase type II in primary breast carcinomas: correlation with clinicopathological features. Virchows Arch A Pathol Anat Histol 1993, 423:51-55
26. Hellemans P, van Dam PA, Geyskens M, van Oosterom AT, Buytaert PH, Van Marck E: Immunohistochemical study of topoisomerase IIα expression in primary ductal carcinoma of the breast. J Clin Pathol 1995, 48:147-150
27. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 1957, 11:359-377
28. Peacock CS, Thompson IW, Norden S: Silver enhancement of polysensitivity for immunoperoxidase staining. J Clin Pathol 1991, 44:756-758
29. Kallioniemi O-P, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991, 49:650-655
30. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA, Isola JJ: Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 1995 (in press)
31. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685
32. Kreipe H, Heidebrecht HJ, Hansen S, Röhlk W, Kubbies M, Wacker HH, Tiemann M, Radzun HJ, Parwaresch R: A new proliferation-associated nuclear antigen in paraffin-embedded tissues by the monoclonal antibody Ki-S1. Am J Pathol 1993, 142:3-9
33. Boege F, Andersen A, Jensen S, Zeidler R, Kreipe H: Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase IIα: delineation of a carboxyl-terminal epitope with peptide antibodies. Am J Pathol 1995, 146:1302-1308
34. Tsai-Pflugfelder M, Liu AF, Tewey KM, Wahng-Peng J, Knutsen T, Huebner K, Croce C, Wang JC: Cloning and sequencing of cDNA encoding human topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 1988, 85:7177-7181
35. Dagerlind Å, Friberg K, Bean AJ, Hökfelt T: Sensitive messenger RNA detection using unfixed tissue-combined radioactive and non-radioactive in situ hybridization histochemistry. Histochemistry 1992, 98:39-49
36. Pelto-Huikko M, Dagerlind Å, Kononen J, Lundberg JM, Villar M, Koistinaho J, Bravo R, Hökfelt T: Neuronal regulation of c-fos, c-jun and junB immediate-early genes in rat adrenal medulla. J Neurosci 1995, 15: 1854-1868
37. Kallioniemi O-P: Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry 1988, 9:164-169
38. Holden JA, Rolfson DH, Wittwer CT: Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 1990, 29:2127-2134
39. Withoff S, Smit EF, Jan Meersma G, van den Berg A, Timmer-Bosscha H, Kok K, Postmus PE, Mulder NH, de Vries EGE, Buys CHCM: Quantitation of DNA topoisomerase IIα messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay. Lab Invest 1994, 71:61-66
40. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH: Alterations in the topoisomerase IIα as well as reduced expression of the DNA topoisomerase IIβ enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 1995, 55:1707-1716
41. Kubo T, Ohga T, Taniguchi K, Kawanami K, Wada M, Kuwano M: DNA topoisomerase II gene expression under transcriptional control in etoposide teniposide-resistant human cancer cells. Cancer Res 1995, 55: 3860-3864
42. Allred DC, Clark GM, Tandon AK, Molina R, Torney DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, McGuire WL: HER2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin Oncol 1992, 10:599-605
43. Gustersson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudemstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn HJ: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992, 10:1049-1056
44. Ravdin PM, Chamness GC: The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers. Gene 1995, 159:19-27